FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Monday

 

Study Finds PoNS Neurostimulator Plus Physical Therapy of Benefit to Advanced MS Patients




























Helius Medical Technologies announced results of a pilot study, demonstrating the benefits of PoNS Therapy — a combination of the investigational Portable Neuromodulation Stimulator (PoNS) device with physical therapy — in patients with advanced MS. Specifically, the treatment was seen to improve both patients’ quality of life, and physical and cognitive abilities.

The study, “Can Exercise Combined with Cranial Nerve Non-Invasive Neuromodulation (CN-NINM) Improve Mobility in Non-Ambulatory People with MS? a Case Study Series” was developed by researchers at the Tactile Communication and Neurorehabilitation Laboratory (TCNL) at the University of Wisconsin, and presented at the recent Consortium of Multiple Sclerosis Centers (CMSC) 2016 Annual Meeting in National Harbor, Maryland.

Neuromodulation is believed to enhance neuroplasticity, the brain’s ability to restructure in response to new experiences, and the core mechanism underlying all cerebral learning and rehabilitation. The non-invasive PoNS device was designed to deliver neurostimulation through the tongue, and has been shown to induce cranial nerve neuromodulation when combined with tailored physical, cognitive or occupational therapy programs, suggesting it could be of use in a variety of neurological diseases.

Researchers assessed the efficacy of PoNS Therapy in six people with advanced MS, with Expanded Disability Status Scale (EDSS) scores of 6.5 to 7.5 (EDSS score range is 0–10). Patients enrolled in the six-month study used the PoNS device combined with physical therapy targeting balance, postural stability, and walking movement or gait.

Improvements were recorded in a number of parameters measuring quality of life, as well as physical and cognitive abilities. Real-life benefits were also observed. These included the ability to again use a walker for local trips, decreased fatigue, overcoming physical obstacles at home, increased independence with day-to-day activities, and greater community access.

“Those with greater functional ability at the beginning of the study (EDSS 6.5-7.0) made the most significant gains but all subjects could be qualified as improved. The intervention shows promise to prolong functional ambulation and independence with daily activity,” said Mitch Tyler, the study’s principal investigator, in a press release.

In a previous MS study sponsored by Helius, the PoNS device was shown to promote neural plasticity and balance after a 14-week treatment period. However, the average EDSS score for these patients was 4.5, not the 7.0 of this newer study, indicating a higher level of disability.

“The patients in this study represent a much more challenging cohort and received PoNSTM Therapy for a longer period (6-months vs. 14-weeks), yet compliance remained high. The outcome is very encouraging,” said Phillippe Deschamps, Helius’ CEO.

Story Source: The above story is based on materials provided by MULTIPLESCLEROSISNEWSTODAY
Note: Materials may be edited for content and length


Go to Newer News Go to Older News